Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moderna, Inc.

27.16
-0.9800-3.48%
Post-market: 27.170.0100+0.04%19:59 EDT
Volume:15.70M
Turnover:428.25M
Market Cap:10.61B
PE:-3.61
High:27.87
Open:27.83
Low:26.87
Close:28.14
52wk High:56.70
52wk Low:23.15
Shares:390.58M
Float Shares:363.29M
Volume Ratio:0.99
T/O Rate:4.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.5273
EPS(LYR):-9.2734
ROE:-27.50%
ROA:-14.78%
PB:1.13
PE(LYR):-2.93

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Lam Research, Rivian Automotive, Eli Lilly

Reuters
·
Oct 24

Moderna Shares Fall 1.7% After Co Halts Development of Cytomegalovirus Vaccine Following Trial Setback

THOMSON REUTERS
·
Oct 23

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Darling Ingredients, Harmony Biosciences

Reuters
·
Oct 23

Moderna Inc : UBS Cuts Target Price to $40 From $70

THOMSON REUTERS
·
Oct 23

BUZZ-U.S. STOCKS ON THE MOVE-Ventyx Biosciences, Dow, Las Vegas

Reuters
·
Oct 23

Piper Sandler Reaffirms Their Buy Rating on Moderna (MRNA)

TIPRANKS
·
Oct 23

Wolfe Adjusts Price Target on Moderna to $16 From $20, Maintains Underperform Rating

MT Newswires Live
·
Oct 23

Moderna Is Maintained at Neutral by Citigroup

Dow Jones
·
Oct 23

Moderna price target lowered to $28 from $30 at Citi

TIPRANKS
·
Oct 23

BUZZ-Moderna shares fall after birth defect vaccine trial misses target

Reuters
·
Oct 23

Moderna Shares Down 4.3% Premarket After Co Halts Development of Birth Defect Vaccine Following Trial Setback

THOMSON REUTERS
·
Oct 23

U.S. RESEARCH ROUNDUP-Avery Dennison, Expedia Group, Hologic

Reuters
·
Oct 23

Moderna : Leerink Partners Cuts Target Price to $12 From $16

THOMSON REUTERS
·
Oct 23

24H | Crypto Shares Jump With Bitfarms up Nearly 6%; Rare Earth Stocks Gain with American Resources up over 3%; Moderna Falls Nearly 4%

Tiger Newspress
·
Oct 23

Stock Track | Moderna Plunges 5.40% After-Hours as CMV Vaccine Fails in Phase 3 Trial

Stock Track
·
Oct 23

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (Cmv) Vaccine Did Not Meet Primary Efficacy Endpoint

THOMSON REUTERS
·
Oct 23

Moderna - Does Not Anticipate Any Impact to Its 2025 Financial Guidance or Its Expectation of Achieving Breakeven in 2028

THOMSON REUTERS
·
Oct 23

Moderna: Will Continue to Evaluate Mrna-1647 in Ongoing Phase 2 Trial in Bone Marrow Transplant Patients

THOMSON REUTERS
·
Oct 23

Moderna - to Discontinue Development of Mrna-1647 in Congenital Cmv

THOMSON REUTERS
·
Oct 23

Moderna Halts CMV Vaccine Development After Phase 3 Trial Misses Efficacy Endpoint

Reuters
·
Oct 23